A panel of microRNA signature in serum for colorectal cancer diagnosis
Metrics: PDF 1646 views | HTML 1722 views | ?
Mingxia Zhu1,2,*, Zebo Huang1,*, Danxia Zhu3,*, Xin Zhou1, Xia Shan4, Lian-wen Qi5, Lirong Wu6, Wenfang Cheng7, Jun Zhu6, Lan Zhang1, Huo Zhang1, Yan Chen8, Wei Zhu1, Tongshan Wang1, Ping Liu1,9
1Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
2Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China
3Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China
4Department of Respiration, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210009, China
5State Key Laboratory of Natural Medicines and Department of Pharmacognosy, China Pharmaceutical University, Nanjing, 210009, China
6Department of Radiation Oncology, Jiangsu Cancer Hospital, Nanjing 210009, China
7Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
8Department of Emergency, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
9Cancer Center of Nanjing Medical University, Nanjing 210029, China
*These authors have contributed equally to this work
Wei Zhu, email: email@example.com
Tongshan Wang, email: firstname.lastname@example.org
Ping Liu, email: email@example.com
Keywords: serum microRNA, colorectal cancer, diagnostic biomarker, qRT-PCR
Received: September 23, 2016 Accepted: January 10, 2017 Published: February 03, 2017
Dysregulated expression of specific microRNAs (miRNAs) in serum has been recognised as promising diagnostic biomarkers for colorectal cancer (CRC). In the initial screening phase, a total of 32 differentially expressed miRNAs were selected by quantitative reverse transcription polymerase chain reaction (qRT-PCR) based Exiqon panel with 3 CRC pool samples and 1 normal control (NC) pool. Using qRT-PCR, selected serum miRNAs were further confirmed in training (30 CRC VS. 30 NCs) and testing stages (136 CRC VS. 90 NCs). We identified that serum levels of miR-19a-3p, miR-21-5p and miR-425-5p were significantly higher in patients with CRC than in NCs. The areas under the receiver operating characteristic (ROC) curve of the three-miRNA panel were 0.86, 0.74 and 0.87 for the training, testing and the external validation stages (30 CRC VS. 18 NCs), respectively. Significantly, elevated expression of the three miRNAs was also observed in CRC tissues (n = 24). Furthermore, the expression levels of the three miRNAs were significantly elevated in exosomes from CRC serum samples (n = 10). In conclusion, we identified a serum three-miRNA panel for the diagnosis of CRC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.